1432502-40-3

Upstream product

• 1432502-39-0 C₁₆H₁₉BrClNO₃ 
• 1432502-38-9 C₂₀H₂₅BrClNO₆ 
• 1432502-37-8 C₂₀H₂₃BrClNO₇ 
• 1432502-36-7 C₁₄H₁₇BrClNO₄ 
• 1213929-66-8 C₉H₉BrClNO₂ 
• 89720-77-4 4-bromo-1-bromomethyl-2-chlorobenzene 
• 185315-48-4 (4-bromo-2-chlorophenyl)methanol 
• 158435-41-7 4-bromo-2-chlorobenzaldehyde 

Downstream Products

• 1432502-41-4 C₁₆H₁₉BrClNO₂ 
• 1432502-42-5 C₁₆H₁₉BrClNO₃ 
• 1432502-43-6 C₁₁H₁₃BrClNO₃*ClH 
• 1432502-44-7 (2R,4R)-4-amino-5-(4-bromo-2-chlorophenyl)-2-hydroxypentanoic acid ethyl ester hydrochloride 

Relevant academic research and scientific papers

NEPRILYSIN INHIBITORS

In one aspect, the invention relates to compounds having the formula I: where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

NEPRILYSIN INHIBITORS

In one aspect, the invention relates to compounds having the formula (I): where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

NEPRILYSIN INHIBITORS

In one aspect, the invention relates to compounds having the formula: where R1-R5 and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

NEPRILYSIN INHIBITORS

In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.